Supernus Pharmaceuticals (SUPN): $1.48 million was the positive money flow into the stock on Thursday and the up/down ratio of ticks was also in favor of the bulls at 2.41. The value of trades done on upticks was $2.52 million, whereas, trades done on downticks were valued at $1.05 million. Money flows are calculated as the dollar value of composite uptick trades minus the dollar value of downtick trades. large traders, also sometimes called as the smart money, block traded $1.05 million worth stocks on upticks, which is a bullish indication. The money flow in block trades was $1.05 million. Supernus Pharmaceuticals (SUPN) fell $0.35 traded at $21.23, a change of -1.62% over the previous day. The stock is 2.86% for the week.
Supernus Pharmaceuticals (SUPN) : The most positive equity analysts on Supernus Pharmaceuticals (SUPN) expects the shares to touch $37, whereas, the least positive believes that the stock will trade at $23 in the short term. The company is covered by 6 Wall Street Brokerage Firms. The average price target for shares are $26.33 with an expected fluctuation of $5.43 from the mean. The stock has recorded a 20-day Moving Average of 7.3% and the 50-Day Moving Average is 12.6%.
Supernus Pharmaceuticals (NASDAQ:SUPN): The stock opened at $21.81 on Thursday but the bulls could not build on the opening and the stock topped out at $21.96 for the day. The stock traded down to $20.53 during the day, due to lack of any buying support eventually closed down at $20.60 with a loss of -4.54% for the day. The stock had closed at $21.58 on the previous day. The total traded volume was 936,495 shares.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on developing and commercializing products for the treatment of central nervous system diseases. The Company launched its two products in neurology for the treatment of epilepsy, which include Oxtellar XR and Trokendi XR. It is also engaged in developing multiple product candidates in psychiatry to address the medical needs and market opportunities in impulsive aggression across several areas (such as attention deficit hyperactivity disorder (ADHD), autism and bipolar disorder), and ADHD. The Company markets its products in the United States through its own specialty sales force and has collaborations with other pharmaceutical companies to license its products outside the United States. Its neurology portfolio consists of Oxtellar XR and Trokendi XR, which are indicated for epilepsy in the United States. Its product candidates include Oxtellar XR, Trokendi XR, SPN-810, SPN-812 and SPN-809.